NCT00004744View on ClinicalTrials.gov

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL

Enrollment

76

Participants

Timeline

Start Date

February 28, 1993

Primary Completion Date

September 30, 1998

Conditions

Multiple Sclerosis

Interventions

DRUG

immune globulin

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Mayo Clinic

OTHER

lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH